DOCSLIB.ORG

The National Institute for Health and Care Excellence

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The National Institute for Health and Care Excellence Appendix B NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Highly Specialised Technology Evaluation Alipogene tiparvovec for treating familial lipoprotein lipase deficiency Draft scope (pre-referral) Draft remit/evaluation objective To evaluate the benefits and costs of alipogene tiparvovec within its licensed indication for treating adults with familial lipoprotein lipase deficiency for national commissioning by NHS England. Background Familial lipoprotein lipase deficiency (LPLD), also known as hyperlipoproteinaemia type I, is an inherited metabolic disorder of lipid metabolism. It is caused by the absence or low activity of lipoprotein lipase, due to mutations in the LPL gene which encodes the enzyme.1 Lipoprotein lipase is the enzyme responsible for uptake of triglycerides from the circulating chylomicrons into the tissues.2 LPLD is characterised by extremely high levels of chylomicrons in the blood. Chylomicrons are triglyceride-rich lipoprotein particles that transport dietary fat absorbed from the intestine to the organs like skeletal muscle, adipose tissue, and cardiac muscle for energy production and storage.3 Familial lipoprotein lipase deficiency may present in infancy or childhood with repetitive episodes of severe, colicky pain in the abdomen, repeated episodes of pancreatitis (inflammation of the pancreas), enlargement of the liver and spleen, and often failure to thrive. The severity of the symptoms depends upon the levels of chylomicrons in the blood. Acute pancreatitis is a life- threatening condition which requires intensive care; repeated attacks of pancreatitis may lead to chronic pancreatitis and diabetes in later life. Diagnosis is sometimes not confirmed until adolescence or adulthood and can involve genetic testing and/or measurement of enzyme activity.4 The prevalence of familial lipoprotein lipase deficiency is estimated to be 1 to 2 per million people which equates to approximately 50 to 100 people in England. Men and women are equally affected.5 Currently the management for LPLD in England consists of restriction of dietary fat intake to no more than 20 g/day in order to keep plasma triglyceride levels low.1 Essential fatty acids (linoleic and alpha linoleic acids) and fat soluble vitamins (vitamins A, D, E and K) supplementations are required for patients on fat restricted diet. In addition to that treatments for hypercholesterolaemia (such as fibrates, nicotinic acids and statins) may be prescribed but have limited value.6 Compliance with the strict dietary regimen is usually difficult to achieve and even with good compliance people often have high triglyceride levels. National Institute for Health and Care Excellence Draft scope for the proposed evaluation of alipogene tiparvovec for treating familial lipoprotein lipase deficiency Issue Date: March 2016 Page 1 of 5 Appendix B The technology Alipogene tiparvovec (Glybera, UniQure and Chiesi) is a gene therapy. It consists of a viral vector designed to deliver and express a variant of human LPL gene into the muscle cells of the patient enabling the muscle cells to produce the lipoprotein lipase enzyme. Alipogene tiparvovec is administered intramuscularly at multiple sites as a one-time treatment. Alipogene tiparvovec has a marketing authorisation for treating adult patients diagnosed with familial lipoprotein lipase deficiency with severe or multiple pancreatitis attacks despite dietary fat restrictions. It is indicated only for patients whose disease has been confirmed by appropriate genetic testing and who have detectable levels of the lipoprotein lipase enzyme in their blood. Intervention(s) Alipogene tiparvovec Population(s) Adults diagnosed with familial lipoprotein lipase deficiency and experiencing severe or multiple pancreatitis attacks despite dietary fat restrictions. Comparators Established clinical management (including dietary fat restrictions) Outcomes The outcome measures to be considered include: reduction in fasting triglyceride levels reduction in chylomicron levels after meals incidence of acute pancreatitis hospitalisation (including admissions to intensive care units) mortality adverse effects of treatment health-related quality of life (for patients and carers). Nature of the disease morbidity and patient clinical disability condition with current standard of care impact of the disease on carer’s quality of life extent and nature of current treatment options Impact of the new clinical effectiveness of the technology technology overall magnitude of health benefits to patients and, when relevant, carers heterogeneity of health benefits within the population National Institute for Health and Care Excellence Draft scope for the proposed evaluation of alipogene tiparvovec for treating familial lipoprotein lipase deficiency Issue Date: March 2016 Page 2 of 5 Appendix B robustness of the current evidence and the contribution the guidance might make to strengthen it treatment continuation rules (if relevant) Cost to the NHS and budget impact in the NHS and PSS, including Personal Social patient access agreements (if applicable) Services (PSS), and robustness of costing and budget impact Value for Money information technical efficiency (the incremental benefit of the new technology compared to current treatment) productive efficiency (the nature and extent of the other resources needed to enable the new technology to be used ) allocative efficiency (the impact of the new technology on the budget available for specialised commissioning) Impact of the whether there are significant benefits other technology beyond than health direct health whether a substantial proportion of the costs benefits, and on the (savings) or benefits are incurred outside of the delivery of the NHS and personal and social services specialised services the potential for long-term benefits to the NHS of research and innovation staffing and infrastructure requirements, including training and planning for expertise. Other considerations Guidance will only be issued in accordance with the marketing authorisation. The appraisal will include consideration of the costs and implications of genetic testing and measurement of enzyme activity, but will not make recommendations on specific diagnostic tests. Related NICE None recommendations and NICE Pathways Related National None Policy National Institute for Health and Care Excellence Draft scope for the proposed evaluation of alipogene tiparvovec for treating familial lipoprotein lipase deficiency Issue Date: March 2016 Page 3 of 5 Appendix B Questions for consultation Have all relevant comparators for alipogene tiparvovec been included in the scope? Which treatments, if any, are considered to be established practice for treating familial lipoprotein lipase deficiency? Are both molecular genetic testing and measurement of lipoprotein lipase enzyme activity required to confirm a diagnosis of LPLD in the NHS? Are there any subgroups of people in whom alipogene tiparvovec is expected to provide greater clinical benefits or more value for money, or other groups that should be examined separately? NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. Please let us know if you think that the proposed remit and scope may need changing in order to meet these aims. In particular, please tell us if the proposed remit and scope: could exclude from full consideration any people protected by the equality legislation who fall within the patient population for which alipogene tiparvovec is licensed; could lead to recommendations that have a different impact on people protected by the equality legislation than on the wider population, e.g. by making it more difficult in practice for a specific group to access the technology; could have any adverse impact on people with a particular disability or disabilities. Please tell us what evidence should be obtained to enable the Highly Specialised Technologies Evaluation Committee to identify and consider such impacts. Do you consider the technology to be innovative in its potential to make a significant and substantial impact on health-related benefits and how it might improve the way that current need is met (is this a ‘step-change’ in the management of the condition)? NICE intends to evaluate this technology through its Highly Specialised Technologies Programme. We welcome comments on the appropriateness of evaluating this topic through this process. (Information on the Institute’s Highly Specialised Technologies interim methods and evaluation processes is available at: http://www.nice.org.uk/media/DE4/9A/HSTCombinedInterimProcessMethods. pdf. National Institute for Health and Care Excellence Draft scope for the proposed evaluation of alipogene tiparvovec for treating familial lipoprotein lipase deficiency Issue Date: March 2016 Page 4 of 5 Appendix B 1 Brunzell J (October 1999 [updated April 2014]) Familial Lipoprotein Lipase Deficiency, GeneReviews. 2 EMA (April 2004) Glybera - Summary of product characteristics. 3 Dixon JB (July 2010) Mechanisms of chylomicron uptake into lacteals, Annals of the New York Academy of Sciences. 1207(Supplement 1): E52–E57. 4 EMA (October 2013) Public summary of opinion on orphan designation: Adeno-associated viral vector expressing lipoprotein lipase for the treatment of lipoprotein lipase deficiency. 5 EMA (November 2012) Recommendation for maintenance of orphan designation at the time of marketing authorisation Glybera (alipogene tiparvovec) for the treatment of lipoprotein lipase deficiency. 6 Heart UK (2012) LPLD04 Fact Sheet - Treatment options. National Institute for Health and Care Excellence Draft scope for the proposed evaluation of alipogene tiparvovec for treating familial lipoprotein lipase deficiency Issue Date: March 2016 Page 5 of 5 .
Load more

Recommended publications
  • (AAV1-LPLS447X) Gene Therapy for Lipoprotein Lipase Deficiency
    Gene Therapy (2013) 20, 361–369 & 2013 Macmillan Publishers Limited All rights reserved 0969-7128/13 www.nature.com/gt ORIGINAL ARTICLE Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial D Gaudet1,2,JMe´ thot1,2,SDe´ry1, D Brisson1,2, C Essiembre1, G Tremblay1, K Tremblay1,2, J de Wal3, J Twisk3, N van den Bulk3, V Sier-Ferreira3 and S van Deventer3 We describe the 2-year follow-up of an open-label trial (CT-AMT-011–01) of AAV1-LPLS447X gene therapy for lipoprotein lipase (LPL) deficiency (LPLD), an orphan disease associated with chylomicronemia, severe hypertriglyceridemia, metabolic complications and potentially life-threatening pancreatitis. The LPLS447X gene variant, in an adeno-associated viral vector of serotype 1 (alipogene tiparvovec), was administered to 14 adult LPLD patients with a prior history of pancreatitis. Primary objectives were to assess the long-term safety of alipogene tiparvovec and achieve a X40% reduction in fasting median plasma triglyceride (TG) at 3–12 weeks compared with baseline. Cohorts 1 (n ¼ 2) and 2 (n ¼ 4) received 3 Â 1011 gc kg À 1, and cohort 3 (n ¼ 8) received 1 Â 1012 gc kg À 1. Cohorts 2 and 3 also received immunosuppressants from the time of alipogene tiparvovec administration and continued for 12 weeks. Alipogene tiparvovec was well tolerated, without emerging safety concerns for 2 years. Half of the patients demonstrated a X40% reduction in fasting TG between 3 and 12 weeks. TG subsequently returned to baseline, although sustained LPLS447X expression and long-term changes in TG-rich lipoprotein characteristics were noted independently of the effect on fasting plasma TG.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
    Atherosclerosis 290 (2019) 140–205 Contents lists available at ScienceDirect Atherosclerosis journal homepage: www.elsevier.com/locate/atherosclerosis 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid ☆ T modification to reduce cardiovascular risk ∗ ∗∗ Authors/Task Force Members (François Macha, ,2, Colin Baigentb, ,2, ∗∗∗ Alberico L. Catapanoc, ,1,2, Konstantinos C. Koskinasd, Manuela Casulae,f,1, Lina Badimong, M. John Chapmanh,i,cm,1, Guy G. De Backerj, Victoria Delgadok, Brian A. Ferencel, Ian M. Grahamm, Alison Hallidayn, Ulf Landmessero,p,q, Borislava Mihaylovar,s, Terje R. Pedersent, Gabriele Riccardiu,1, Dimitrios J. Richterv, Marc S. Sabatinew, Marja-Riitta Taskinenx,1, Lale Tokgozogluy,1, Olov Wiklundz), ESC National Cardiac Societies (Djamaleddine Nibouchean, Parounak H. Zelveianao, Peter Siostrzonekap, Ruslan Najafovaq, Philippe van de Bornear, Belma Pojskicas, Arman Postadzhiyanat, Lambros Kyprisau, Jindřich Špinarav, Mogens Lytken Larsenaw, Hesham Salah Eldinax, Margus Viigimaaay, Timo E. Strandbergaz, Jean Ferrièresba, Rusudan Agladzebb, Ulrich Laufsbc, Loukianos Rallidisbd, László Bajnokbe, Thorbjörn Gudjónssonbf, Vincent Maherbg, Yaakov Henkinbh, Michele Massimo Guliziabi, Aisulu Mussagaliyevabj, Gani Bajraktaribk, Alina Kerimkulovabl, Gustavs Latkovskisbm, Omar Hamouibn, Rimvydas Slapikasbo, Laurent Visserbp, Philip Dinglibq, Victoria Ivanovbr, Aneta Boskovicbs, Mbarek Nazzibt, Frank Visserenbu, Irena Mitevskabv, Kjetil Retterstølbw, Piotr Jankowskibx, Ricardo Fontes-Carvalhoby, Dan Gaitabz, Marat Ezhovca,
    [Show full text]
  • Small Dense Low-Density Lipoprotein: Biomarker Or Potential Drug Target?
    Published online: 02.10.2019 THIEME 92 SmallReview Dense Article Low-Density Lipoprotein Samanta Small Dense Low-Density Lipoprotein: Biomarker or Potential Drug Target? Basabdatta Samanta1 1Department of Biochemistry, Burdwan Medical College, West Address for correspondence Basabdatta Samanta, MBBS, MD, Bengal, India DNB, Department of Biochemistry, Burdwan Medical College, Burdwan 713104, West Bengal, India (e-mail: [email protected]). Ann Natl Acad Med Sci (India) 2019;55:92–97 Abstract Ischemic heart disease is currently an epidemic affecting individuals worldwide. Increased incidence along with earlier onset of disease has led to the constant search for biomarkers that will help in earlier identification and treatment of at risk individuals. Small dense low-density lipoprotein (sdLDL) is the atherogenic subtype of low-densi- ty lipoprotein (LDL). It is smaller in size and higher in density in comparison to other LDL subtypes. Higher levels of sdLDL have been found to be associated with increased incidence of ischemic heart disease and adverse outcomes. Properties including decreased resistance to oxidative stress and prolonged residence time in the circula- tion account for its increased atherogenic potential. Hence intervention approaches targeting sdLDL directly in at risk individuals may be beneficial. Genetic, lifestyle, and environmental factors affect sdLDL levels. But the main deter- mining factor is the level of triglycerides (TGs). Higher TG levels are associated with higher levels of very low density lipoprotein (VLDL) 1 and sdLDL. Various drugs Keywords have been used for targeting sdLDL with varying outcomes; drugs tried out include ► ischemic heart disease statins, fibrates, niacin, cholesterol ester transfer protein inhibitors and sodium-glu- ► small dense low - cose co-transporter-2 inhibitors.
    [Show full text]
  • Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark
    A Service of Leibniz-Informationszentrum econstor Wirtschaft Leibniz Information Centre Make Your Publications Visible. zbw for Economics Kaiser, Ulrich; Mendez, Susan J.; Rønde, Thomas Working Paper Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark ZEW Discussion Papers, No. 10-062 Provided in Cooperation with: ZEW - Leibniz Centre for European Economic Research Suggested Citation: Kaiser, Ulrich; Mendez, Susan J.; Rønde, Thomas (2010) : Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark, ZEW Discussion Papers, No. 10-062, Zentrum für Europäische Wirtschaftsforschung (ZEW), Mannheim This Version is available at: http://hdl.handle.net/10419/41440 Standard-Nutzungsbedingungen: Terms of use: Die Dokumente auf EconStor dürfen zu eigenen wissenschaftlichen Documents in EconStor may be saved and copied for your Zwecken und zum Privatgebrauch gespeichert und kopiert werden. personal and scholarly purposes. Sie dürfen die Dokumente nicht für öffentliche oder kommerzielle You are not to copy documents for public or commercial Zwecke vervielfältigen, öffentlich ausstellen, öffentlich zugänglich purposes, to exhibit the documents publicly, to make them machen, vertreiben oder anderweitig nutzen. publicly available on the internet, or to distribute or otherwise use the documents in public. Sofern die Verfasser die Dokumente unter Open-Content-Lizenzen (insbesondere CC-Lizenzen) zur Verfügung gestellt haben sollten, If the documents have been made available under an Open gelten abweichend von diesen Nutzungsbedingungen die in der dort Content Licence (especially Creative Commons Licences), you genannten Lizenz gewährten Nutzungsrechte. may exercise further usage rights as specified in the indicated licence. www.econstor.eu Dis cus si on Paper No. 10-062 Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark Ulrich Kaiser, Susan J.
    [Show full text]
  • LAI Expert Consensus Statement
    st st 8 Supplement to Journal of The Association of Physicians of India ■ Published on 1 of Every Month 1 November, 2020 Lipid Association of India Expert Consensus Statement on Management of Dyslipidemia in Indians 2020: Part III Expert Consensus Panel: Raman Puri, Chairman1, Vimal Mehta, Co-Chair2, SS Iyengar, Co-Chair3, SN Narasingan, Co-Chair4, P Barton Duell5, GB Sattur6, Krishnaswami Vijayaraghavan7, JC Mohan8, SK Wangnoo9, Jamshed Dalal10, D Prabhakar11, Rajeev Agarwal12, Manish Bansal13, Jamal Yusuf2, Saibal Mukhopadhyay2, Sadanand Shetty14, Prabhash Chand Manoria15, Avishkar Sabharwal16, Akshayaya Pradhan17, Rahul Mehrotra18, Sundeep Mishra19, Sonika Puri20, A Muruganathan21, Abdul Hamid Zargar22, Rashida Melinkari Patanwala23, Soumitra Kumar24, Neil Bardoloi25, KK Pareek26, Aditya Kapoor27, Ashu Rastogi28, Devaki R Nair29, Altamash Shaikh30, Chandra Mani Adhikari31, Muhammad Shoaib Momen Majumder32, Dheeraj Kapoor33, Madhur Yadav34, MR Mubarak35, AK Pancholia36, Rakesh Kumar Sahay37, Rashmi Nanda38, Nathan D Wong39 Introduction proposed by Lipid Association of India regarding various interventions based (LAI),8 identification and application on scientific evidence. The section on ndia is in the middle of an epidemic of lipid markers like lipoprotein (a) low LDL-C levels sums the evidence to Iof atherosclerotic cardiovascular [Lp(a)] and apolipoprotein B (apo the present date and gives justification disease (ASCVD) which is showing B) for risk stratification and control for lower proposed LDL-C goals. Since no signs of abating.1,2
    [Show full text]
  • The Personalized Medicine Report
    THE PERSONALIZED MEDICINE REPORT 2017 · Opportunity, Challenges, and the Future The Personalized Medicine Coalition gratefully acknowledges graduate students at Manchester University in North Manchester, Indiana, and at the University of Florida, who updated the appendix of this report under the guidance of David Kisor, Pharm.D., Director, Pharmacogenomics Education, Manchester University, and Stephan Schmidt, Ph.D., Associate Director, Pharmaceutics, University of Florida. The Coalition also acknowledges the contributions of its many members who offered insights and suggestions for the content in the report. CONTENTS INTRODUCTION 5 THE OPPORTUNITY 7 Benefits 9 Scientific Advancement 17 THE CHALLENGES 27 Regulatory Policy 29 Coverage and Payment Policy 35 Clinical Adoption 39 Health Information Technology 45 THE FUTURE 49 Conclusion 51 REFERENCES 53 APPENDIX 57 Selected Personalized Medicine Drugs and Relevant Biomarkers 57 HISTORICAL PRECEDENT For more than two millennia, medicine has maintained its aspiration of being personalized. In ancient times, Hippocrates combined an assessment of the four humors — blood, phlegm, yellow bile, and black bile — to determine the best course of treatment for each patient. Today, the sequence of the four chemical building blocks that comprise DNA, coupled with telltale proteins in the blood, enable more accurate medical predictions. The Personalized Medicine Report 5 INTRODUCTION When it comes to medicine, one size does not fit all. Treatments that help some patients are ineffective for others (Figure 1),1 and the same medicine may cause side effects in only certain patients. Yet, bound by the constructs of traditional disease, and, at the same time, increase the care delivery models, many of today’s doctors still efficiency of the health care system by improving prescribe therapies based on population averages.
    [Show full text]
  • 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
    Atherosclerosis 290 (2019) 140–205 Contents lists available at ScienceDirect Atherosclerosis journal homepage: www.elsevier.com/locate/atherosclerosis 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid ☆ T modification to reduce cardiovascular risk ∗ ∗∗ Authors/Task Force Members (François Macha, ,2, Colin Baigentb, ,2, ∗∗∗ Alberico L. Catapanoc, ,1,2, Konstantinos C. Koskinad, Manuela Casulae,f,1, Lina Badimong, M. John Chapmanh,i,cm,1, Guy G. De Backerj, Victoria Delgadok, Brian A. Ferencel, Ian M. Grahamm, Alison Hallidayn, Ulf Landmessero,p,q, Borislava Mihaylovar,s, Terje R. Pedersent, Gabriele Riccardiu,1, Dimitrios J. Richterv, Marc S. Sabatinew, Marja-Riitta Taskinenx,1, Lale Tokgozogluy,1, Olov Wiklundz), ESC Committee for Practice Guidelines (CPG) (Stephan Windeckeraa, Victor Aboyansab, Colin Baigentac, Jean-Philippe Colletab, Veronica Deanab, Victoria Delgadoad, Donna Fitzsimonsac, Chris P. Galeac, Diederick Grobbeead, Sigrun Halvorsenae, Gerhard Hindricksaf, Bernard Iungab, Peter Jüniag, Hugo A. Katusaf, Ulf Landmesseraf, Christophe Leclercqab, Maddalena Lettinoah, Basil S. Lewisai, Bela Merkelyaj, Christian Muelleraa, Steffen Petersenac, Anna Sonia Petronioah, Dimitrios J. Richterak, Marco Roffiaa, Evgeny Shlyakhtoal, Iain A. Simpsonac, Miguel Sousa-Uvaam, Rhian M. Touyzac), ESC National Cardiac Societies (Djamaleddine Nibouchean, Parounak H. Zelveianao, Peter Siostrzonekap, Ruslan Najafovaq, Philippe van de Bornear, Belma Pojskicas, Arman Postadzhiyanat, Lambros Kyprisau, Jindřich Špinarav, Mogens Lytken
    [Show full text]
  • Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis
    RESEARCH ARTICLE Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis Daniel Gaudet,1,* Erik S. Stroes,2 Julie Me´ thot,1 Diane Brisson,1 Karine Tremblay,1 Sophie J. Bernelot Moens,2 Giorgio Iotti,3 Irene Rastelletti,3 Diego Ardigo,3 Deyanira Corzo,4 Christian Meyer,4 Marc Andersen,4 Philippe Ruszniewski,5 Mark Deakin,6 and Marco J. Bruno7 1Ecogene-21 Clinical and Translational Research Center and Lipidology Unit, Community Genetic Medicine Centre, Department of Medicine, Universite´ de Montreal, Montreal, Canada; 2Academic Medical Center, Amsterdam, The Netherlands; 3Chiesi Farmaceutici, Parma, Italy; 4uniQure B.V., Amsterdam, The Netherlands; 5Beaujon Hospital, Denis Diderot University, Paris, France; 6University Hospital of North Midlands, Stoke-on-Trent, United Kingdom; 7Erasmus Medical Centre, Rotterdam, The Netherlands. Alipogene tiparvovec (Glybera) is a gene therapy product approved in Europe under the ‘‘exceptional cir- cumstances’’ pathway as a treatment for lipoprotein lipase deficiency (LPLD), a rare genetic disease re- sulting in chylomicronemia and a concomitantly increased risk of acute and recurrent pancreatitis, with potentially lethal outcome. This retrospective study analyzed the frequency and severity of pancreatitis in 19 patients with LPLD up to 6 years after a single treatment with alipogene tiparvovec. An independent adjudication board of three pancreas experts, blinded to patient identification and to pre- or post-gene therapy period, performed a retrospective review of data extracted from the patients’ medical records and categorized LPLD-related acute abdominal pain events requiring hospital visits and/or hospitalizations based on the adapted 2012 Atlanta diagnostic criteria for pancreatitis.
    [Show full text]
  • Small Dense Low-Density Lipoprotein: Biomarker Or Potential Drug Target?
    Published online: 2019-10-02 THIEME 92 SmallReview Dense Article Low-Density Lipoprotein Samanta Small Dense Low-Density Lipoprotein: Biomarker or Potential Drug Target? Basabdatta Samanta1 1Department of Biochemistry, Burdwan Medical College, West Address for correspondence Basabdatta Samanta, MBBS, MD, Bengal, India DNB, Department of Biochemistry, Burdwan Medical College, Burdwan 713104, West Bengal, India (e-mail: [email protected]). Ann Natl Acad Med Sci (India) 2019;55:92–97 Abstract Ischemic heart disease is currently an epidemic affecting individuals worldwide. Increased incidence along with earlier onset of disease has led to the constant search for biomarkers that will help in earlier identification and treatment of at risk individuals. Small dense low-density lipoprotein (sdLDL) is the atherogenic subtype of low-densi- ty lipoprotein (LDL). It is smaller in size and higher in density in comparison to other LDL subtypes. Higher levels of sdLDL have been found to be associated with increased incidence of ischemic heart disease and adverse outcomes. Properties including decreased resistance to oxidative stress and prolonged residence time in the circula- tion account for its increased atherogenic potential. Hence intervention approaches targeting sdLDL directly in at risk individuals may be beneficial. Genetic, lifestyle, and environmental factors affect sdLDL levels. But the main deter- mining factor is the level of triglycerides (TGs). Higher TG levels are associated with higher levels of very low density lipoprotein (VLDL) 1 and sdLDL. Various drugs Keywords have been used for targeting sdLDL with varying outcomes; drugs tried out include ► ischemic heart disease statins, fibrates, niacin, cholesterol ester transfer protein inhibitors and sodium-glu- ► small dense low - cose co-transporter-2 inhibitors.
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • Alipogene Tiparvovec (AMT-011, Glybera) for Lipoprotein Lipase Deficiency
    Alipogene tiparvovec (AMT-011, Glybera) for lipoprotein lipase deficiency February 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes. The National Horizon Scanning Centre Research Programme is part of the National Institute for Health Research February 2009 National Horizon Scanning Centre News on emerging technologies in healthcare Alipogene tiparvovec (Glybera) for lipoprotein lipase deficiency Target group • Lipoprotein lipase deficiency - also known as familial chylomicronaemia or hyperlipoproteinaemia type I. Background Lipoprotein lipase deficiency (LPLD) is an inherited metabolic disorder, characterised by abnormally elevated plasma concentrations of chylomicrons and triglycerides. LPLD includes patients classified as having hyperlipoproteinaemia type 1 (also known as familial chylomicronaemia) due to a deficiency of lipoprotein lipase (LPL) and those with a deficiency of apolipoprotein C-II, a lipase activating protein. LPL hydrolyses the triglyceride component of circulating chylomicrons and very low density lipoproteins (VLDL). When LPL activity is reduced, chylomicrons accumulate within the bloodstream and cause symptoms such as: abdominal pain, an enlarged spleen and liver, eruptive xanthomas and potentially lethal pancreatitis. The gene encoding for LPL is located on chromosome 8 and is expressed mainly in skeletal muscle, adipose tissue, and heart muscle. Technology description Alipogene tiparvovec (AMT-011, Glybera) is an adeno-associated viral vector (AAV1) based gene therapy, administered intramuscularly (IM) at multiple-sites in a single session. AAV1 carrying the human variant LPLS447X gene is delivered to skeletal muscle, where it becomes active.
    [Show full text]